您的位置: 首页 > 2021年11月 第52卷 第6期 > 文字全文
2023年7月 第38卷 第7期11
目录

356例甲状腺Bethesda Ⅲ类结节的细胞病理学诊断分析

Cytopathological diagnosis of BethesdaⅢ thyroid nodules: a report of 356 cases

来源期刊: 广州医药 | 14-17 发布时间:2021-11-26 收稿时间:2025/11/13 18:00:48 阅读量:15
作者:
关键词:
甲状腺细针吸取细胞学Bethesda Ⅲ类亚分类甲状腺乳头状癌
thyroidfine needle aspiration cytologyBethesda IIIsubcategoriespapillary thyroid carcinoma
DOI:
10.3969/j.issn.1000-8535.2021.06.004
收稿时间:
2021-04-26 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨甲状腺Bethesda Ⅲ类(AUS/FLUS)结节的诊断原因,以及亚分类在预测结节恶性风险(risk of malignancy,ROM)中的价值。方法 收集356例Bethesda Ⅲ结节患者,对其诊断原因, ROM及亚分类进行总结分析。结果 在97例手术切除标本中,72例恶性肿瘤均为甲状腺乳头状癌(papillary thyroid carcinoma,PTC),Bethesda Ⅲ类的ROM为74.2%。影响PTC诊断的主要原因有病灶小、穿刺细胞量稀少、缺乏乳头状结构及细胞核特征不典型;次要原因有间质显著纤维化或钙化、涂片不合格、固定不当、染色不佳及细胞学诊断经验欠缺等。Bethesda Ⅲ类的亚分类:132例为低风险组,其中12例手术切除,ROM为8.3%;122例为高风险组,其中70例手术切除,ROM为92.9%;102例为中风险组,其中15例手术切除,ROM为40.0%;高风险组和低/中风险组之间的差异有统计学意义(P<0.05)。结论 Bethesda Ⅲ类的诊断具有一定的主观性和经验性,而对Bethesda Ⅲ类结节进行风险相关的亚分类,有助于实现更好的ROM分层并改善此类病变的临床管理。
Objective To investigate the diagnostic causes of Bethesda Ⅲ (AUS/FLUS) thyroid nodules and the value of subcategories in predicting risk of malignancy (ROM) of thyroid nodules. Methods The data of 356 cases of Bethesda Ⅲ nodules were collected, and the causes, ROM and subcategories were summarized. Results In 97 resected specimens, 72 were diagnosed as papillary thyroid carcinoma (PTC), and the ROM of Bethesda Ⅲ was 74.2%. The main factors affecting the diagnosis of PTC were small lesions, few puncture cells, atypical nuclear features and lack of papillary structure. Secondary factors included significant interstitial fibrosis or calcification, unqualified smear, improper fixation, poor staining and lack of cytological diagnosis experience. According to the subcategories of Bethesda Ⅲ, 132 cases were included in low-risk group, nodules of 12 cases in the group were resected, which ROM was 8.3%; 122 cases were included in high-risk group, nodules of 70 cases were resected, which ROM was 92.9%; 102 cases were included in middle-risk group, nodules of 15 cases were resected, which ROM was 40.0%. The differences between high-risk group and low/medium-risk group were statistically significant (P<0.05). Conclusion The diagnosis of Bethesda Ⅲ is subjective and empirical in some degree, and the risk related subcategories of Bethesda Ⅲ nodules is helpful to achieve better ROM stratification and improve the clinical management of the disease.
1、 KIM S J,ROH J,BAEK J H,et al. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology [J]. Cytopathology,2017,28 (1):65-73. KIM S J,ROH J,BAEK J H,et al. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology [J]. Cytopathology,2017,28 (1):65-73.
2、 OLSON M T,CLARK D P,EROZAN Y S,et al. Spectrum of risk of malignancy in subcategories of “atypia of undetermined significance” [J]. Acta Cytol,2011,55 (6):518-525. OLSON M T,CLARK D P,EROZAN Y S,et al. Spectrum of risk of malignancy in subcategories of “atypia of undetermined significance” [J]. Acta Cytol,2011,55 (6):518-525.
3、 HYEON J,AHN S,SHIN J H,et al. The Prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results [J]. Cancer Cytopathol,2014,122 (5):368-376. HYEON J,AHN S,SHIN J H,et al. The Prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results [J]. Cancer Cytopathol,2014,122 (5):368-376.
4、 CIBAS E S,ALI S Z. The 2017 Bethesda system for reporting thyroid cytopathology [J]. J Am Soc Cytopathol,2017,6 (6):217- 222. CIBAS E S,ALI S Z. The 2017 Bethesda system for reporting thyroid cytopathology [J]. J Am Soc Cytopathol,2017,6 (6):217- 222.
5、 刘红刚,刘东戈,余小蒙,等. 甲状腺细胞病理学Bethesda报告系统:定义、标准和注释[M].2版.北京:北京科学技术出版社,2020:8. 刘红刚,刘东戈,余小蒙,等. 甲状腺细胞病理学Bethesda报告系统:定义、标准和注释[M].2版.北京:北京科学技术出版社,2020:8.
6、 车娜,孙保存,刘增辉,等. 1241例甲状腺结节US-FNAB病例临床特点与病理结果分析[J]. 中国肿瘤临床,2018, 45(7):350-354. 车娜,孙保存,刘增辉,等. 1241例甲状腺结节US-FNAB病例临床特点与病理结果分析[J]. 中国肿瘤临床,2018, 45(7):350-354.
7、 孙大菊,张文杰,闻春艳. 10800例甲状腺细针穿刺细胞学病理诊断分析[J]. 中国实验病理学,2015, 19(11):1916-1917. 孙大菊,张文杰,闻春艳. 10800例甲状腺细针穿刺细胞学病理诊断分析[J]. 中国实验病理学,2015, 19(11):1916-1917.
8、 ALSHAIKH S,HARB Z,ALJUFAIRI E,et al. Classification of thyroid fine-needle aspiration cytology into Bethesda categories: an institutional experience and review of the literature [J]. Cytojournal,2018, 16(15):4. ALSHAIKH S,HARB Z,ALJUFAIRI E,et al. Classification of thyroid fine-needle aspiration cytology into Bethesda categories: an institutional experience and review of the literature [J]. Cytojournal,2018, 16(15):4.
9、 林建龙,钟国栋,王鸿程,等. 2386例甲状腺细针穿刺液基细胞学病理诊断分析[J]. 诊断病理学杂志,2018, 25(2):112-117. 林建龙,钟国栋,王鸿程,等. 2386例甲状腺细针穿刺液基细胞学病理诊断分析[J]. 诊断病理学杂志,2018, 25(2):112-117.
10、 UGURLUOGLU C,DOBUR F,KARABAGLI P,et al. Fine needle aspiration biopsy of thyroid nodules: cytologic and histopathologic correlation of 1096 patients [J]. Int J Clin Exp Pathol,2015,8 (11):14800-14805. UGURLUOGLU C,DOBUR F,KARABAGLI P,et al. Fine needle aspiration biopsy of thyroid nodules: cytologic and histopathologic correlation of 1096 patients [J]. Int J Clin Exp Pathol,2015,8 (11):14800-14805.
11、 刘军,余小蒙,彭继英,等. 超声引导下甲状腺细针穿刺活检992例的临床与病理分析 [J]. 广东医学,2017, 38(4):588-591. 刘军,余小蒙,彭继英,等. 超声引导下甲状腺细针穿刺活检992例的临床与病理分析 [J]. 广东医学,2017, 38(4):588-591.
12、 孟媛,肖雨. 甲状腺细针穿刺“意义不能明确结节”恶性风险度研究进展[J]. 广东医学,2020, 41(13):1395-1398. 孟媛,肖雨. 甲状腺细针穿刺“意义不能明确结节”恶性风险度研究进展[J]. 广东医学,2020, 41(13):1395-1398.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录